Immuno-Chemotherapy Combo Extends Lung Cancer Victim's Survival Period

Immuno-Chemotherapy Combo Extends Lung Cancer Victim's Survival Period

In one, scientists at New York University conducted a study involving more than 600 patients with advanced lung cancer.

The five key Principles for improving lung cancer outcomes have been well established: patient-centered care; timely access to evidence-based pathways of care; multidisciplinary care; co-ordination, communication and continuity of care; and data-driven improvements.

The findings, published in the the New England Journal of Medicine, were reported on Monday at the American Association for Cancer Research annual meeting in Chicago.

"If you want to see long-term survival, youve got to give immunotherapy as soon as possible", Herbst said. "We have patients on these immunotherapies alive more than eight years".

Notably, the incidence rate of lung cancer among non-smoking Chinese females is rising comparatively faster compared with those in western countries.

Other studies in lung cancer have involved another checkpoint inhibitor, nivolumab, or Opdivo (made by Bristol-Myers Squibb), which works in a similar way to pembrolizumab.

After 18 months, recurrence-free survival was 73 per cent compared to the clinical average of around 50 per cent.

One group of 400 patients received standard chemotherapy and the immunotherapy drug pembrolizumab, while a smaller group of patients received chemotherapy. It's a sign that checkpoint inhibitors like Keytruda, which unleash a patient's immune system to fight cancer, are on their way to becoming first-line therapies for cancer.

But patients in the immunotherapy group had more kidney problems, more immune-related adverse events and were more likely to stop treatment because of side effects. But that is advance in this cancer.

The estimated survival rate after 12 months for those that just received chemotherapy was 49.4 percent - in other words, just under half of those patients survived for a year.